Trending Topics

and/or

96 Trending Topics found

Targeted Therapy, Sorafenib, Shows Promise as First-Line Treatment for Previously Untreatable Rare Tumors

In patients with progressive, refractory, or symptomatic desmoid tumors, sorafenib (Nexavar®) significantly improved progression-free survival (PFS) and induced durable responses. This study defined an active therapy for desmoid tumors that appears effective in slowing disease progression.

  • Wednesday, December 19, 2018

Memorial Sloan Kettering Breast Cancer Experts to Gather at Annual San Antonio Breast Cancer Symposium

Experts from all specialties of breast cancer treatment will attend the 2018 San Antonio Breast Cancer Symposium from December 4 through 8. It is the largest annual meeting devoted solely to the latest in breast cancer advances. The meeting will highlight emerging research and also tackle some of the larger issues facing people with breast cancer and the doctors who treat them.

  • Monday, December 3, 2018

Memorial Sloan Kettering Researchers at ASH Annual Meeting

The world’s most comprehensive hematology meeting of the year will take place in San Diego, California, from December 1 through 4. Memorial Sloan Kettering experts are available to comment on research and breaking news out of the meeting. Follow the meeting live on Twitter using the hashtag #ASH18. For more information and to set up interviews or access photos and video, email Rebecca Williams at  mediastaff@mskcc.org.

  • Thursday, November 29, 2018

Milestone Precision Medicine Decision: FDA Approves the First Treatment with an Initial Tumor-Agnostic Indication

The US Food and Drug Administration (FDA) has approved the drug larotrectinib for cancers caused by a genetic mutation called a TRK fusion. Today’s decision marks a transformation in the field of precision medicine as this is the first time that an entirely new treatment has received a tumor-agnostic indication at its initial approval, meaning that the drug was approved based on mutation type rather than on where in the body the tumor originated.

  • Monday, November 26, 2018

Adding Meaning to Their Miles: Fred’s Team Takes the TCS New York City Marathon

More than 50,000 runners traversed 26.2 miles across five boroughs for the TCS New York City Marathon. Among them were 925 participants who ran in support of Fred’s Team. Fred’s Team is the running program for Memorial Sloan Kettering Cancer Center (MSK), which is dedicated to moving closer to a world without cancer.

  • Friday, November 9, 2018

The Biden Cancer Summit: Finding Keys to Unlock Cancer Breakthroughs

Recently, thousands of people convened in Washington, DC, and across 450 communities nationwide for the Biden Cancer Summit, to build on former Vice President Joe Biden and Jill Biden’s commitment to ending cancer as we know it.

  • Wednesday, October 31, 2018

New Study Looks at Low-Dose Radiation That Could Make CAR T Cell Therapy More Effective

A preclinical study published in the journal Molecular Therapy by researchers at Memorial Sloan Kettering (MSK) provides evidence that radiation therapy could improve the efficacy of CAR T cell therapy for solid tumors.

  • Thursday, October 25, 2018

Actionable Insight to Raise Breast Health Awareness

Women want to understand and decrease their risk of breast cancer, and Nicole Saphier, MD, Director of Breast Imaging at MSK Monmouth, wants to ensure that women make the right decisions when it comes to their breast health this October, in honor of Breast Cancer Awareness Month, and every day.

  • Tuesday, October 23, 2018

New Study Shows Immunotherapy and Chemo Combination Extends Survival for People with Hard-to-Treat Breast Cancer

MSK experts comment on a new international study that looked at combination therapy for triple-negative breast cancer.

  • Saturday, October 20, 2018

FDA Expands Use of HPV Vaccine: What It Means in the Fight against Cancer

The US Food and Drug Administration has updated its recommendations for the use of Gardasil 9, the vaccine that protects against human papillomavirus (HPV), to include people age 27 to 45. Previously, Gardasil 9 was only approved for use in those between age nine and 26. 

  • Thursday, October 18, 2018